Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Andrx’ Declining Revenue Reflects Cost Of Investments

This article was originally published in The Pink Sheet Daily

Executive Summary

The company says its decline in total revenues is reflective of its continued development of manufacturing processes and facilities.

You may also be interested in...

Teva Will Inherit OAI Status Of Andrx' Oral Contraceptives

FDA will continue to block approval of Andrx' oral contraceptives until manufacturing issues are resolved despite the company's intention to transfer its pending ANDAs to Teva

Andrx’ ANDA Approvals On Hold Pending Resolution Of Manufacturing Issues

The company has been placed in “Official Action Indicated” status following an FDA inspection that resulted in a “Form 483.”

NEJM, JAMA Editorials Give Opposing Opinions Of Mandatory HPV Vaccination

Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts